Regeneron (REGN) Accounting Changes Will Result in Downward Adjustment - Morgan Stanley
April 7, 2020 7:35 AM
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $410.00 price target on (NASDAQ: REGN) after management announced that ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
